for the BADBIR Study Group IMPORTANCE Patients with psoriasis enrolled in clinical trials of biologics may not be representative of the real-world population. There is evidence that patients ineligible for such trials have a greater risk of serious adverse events (SAEs), but the effect on drug discontinuation and effectiveness are unknown.
B
iologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. However, stringent eligibility criteria applied in clinical trials of biologic therapies for psoriasis can result in selection bias and uncertainty of the external validity to real-world psoriasis populations. This is important because estimating the gap between efficacy and effectiveness is fundamental to evidence-based, costeffective prescribing.
There are limited data quantifying the differences between clinical trial findings and clinical practice for biologic therapies in the treatment of psoriasis. One approach to investigating relevance of trial data are to examine the impact of eligibility criteria applied to a real-world population of patients with psoriasis; 29.8% patients registered in the Spanish Registry of Adverse Events Associated With Biologic Drugs in Dermatology (BIOBADADERM) would be ineligible for clinical trials using common eligibility criteria identified from a meta-analysis of randomized clinical trials investigating systemic and biologic treatments for psoriasis.
1,2 An increased risk of serious adverse events (SAEs) was detected for ineligible patients in the first 12 months of treatment (incidence rate ratio [IRR], 2.6; 95% CI, 1.5-4.5), indicating that the safety of real-world patients is not adequately represented in clinical trials. 1 Differences in drug discontinuation between eligible and ineligible patients are yet to be determined, and the gap between efficacy and effectiveness is also unknown.
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The British Association of Dermatologists Biologics Intervention Register (BADBIR) is a prospective pharmacovigilance register of patients with psoriasis recruited from 157 dermatology centers in the United Kingdom and Republic of Ireland. 4 The BADBIR is a representative cohort of biologic prescribing in clinical practice enabling the investigation of the gap between clinical trial and real-world outcomes. Our hypothesis was that patients identified as ineligible for clinical trials would have lower effectiveness, and greater rates of drug discontinuation and SAEs compared with eligible patients. The objectives of the study were to: 1. identify the eligibility criteria applied in phase 3 clinical trials of biologics in psoriasis; 2. determine the proportion of patients registered to BADBIR who would have been eligible for those trials; and 3. determine whether drug discontinuation, effectiveness, and the incidence of SAEs in the first 12 months of biologic exposure differ by eligibility criteria.
Methods

Study Design and Setting
Patients registering to BADBIR receiving etanercept (enbrel only), adalimumab, or ustekinumab who completed at least 1 follow-up up to December 1, 2016 , were included in the analysis. BADBIR received approval from the North West Research Ethics Committee in March 2007. All patients provided written informed consent in accordance with the Declaration of Helsinki. Participants were not compensated.
Baseline Assessments
Patients were recruited during routine appointments at dermatology centers within 6 months of initiating or switching to a biologic or conventional systemic therapy. All data were recorded onto a web-based database including Psoriasis Area and Severity Index (PASI) and clinical history (comorbidities with year of onset, previous antipsoriatic therapies, concomitant therapies). A PASI value of 10 or more is not required for patients registering on a biologic therapy in BADBIR. 
Follow-up Assessments
Assessments were undertaken by the dermatology team at 6-monthly intervals for the first 3 years, then annually. These included PASI values and changes in therapy for psoriasis (temporary cessation; discontinuation, including the stop reason; dose changes; initiation or switching). Medical records were reviewed for any adverse events since the previous visit. Serious adverse events (SAEs) were untoward medical occurrences that were considered to represent a hazard to the patient, including: death, overnight hospitalization, immediately life-threatening, intravenous antimicrobial administration, loss of function or disability, congenital malformation/birth defect, medically important event. Examples of medically important events include malignant abnormalities and pregnancies. All SAEs were subsequently coded to the Medical Dictionary for Regulatory Activities (MedDRA).
Clinical Trial Eligibility Criteria
Eligibility criteria were extracted from phase 3 licensing trials for etanercept, 5-7 adalimumab, 8,9 and ustekinumab 10,11 (eTable 1intheSupplement); further resources including http://www .clinicaltrials.gov, http://www.amgentrials.com, clinical study reports (AbbVie), and related articles 12,13 were searched for additional eligibility criteria. Clinical trial study protocols were requested from AbbVie, Janssen, and Pfizer, but were not made available. Licensing trials rarely exceeded 12 months in duration and the most common primary outcomes were number of adverse events and achievement of PASI 75 at specific time points (eTable 1 in the Supplement).
The eligibility criteria used in the present study are listed in Table 1 . It is possible for patients registering to BADBIR to enter
Key Points
Question What proportion of patients with psoriasis who were taking a biologic and registered to the British Association of Dermatologists Biologics Intervention Register (BADBIR) would have been eligible for the pivotal licensing trials of biologics for psoriasis?
Findings In this observational study of 7136 patients with psoriasis, those identified as ineligible for clinical trials had lower effectiveness and higher rates of serious adverse events while receiving biologic therapy in the first 12 months compared with patients identified as eligible.
Meaning Clinical trial findings of biologic therapies for psoriasis are not representative of real-world patients who would have been excluded from such trials.
a baseline PASI value of less than 10, or have a missing date for a PASI value. Patients in BADBIR would otherwise be categorized as eligible who had a baseline PASI value insufficient for entry into a clinical trial. A missing baseline PASI date, or baseline PASI recorded after the initiation of therapy (also categorized as missing) were investigated separately. The prevalence of 2 or more comorbidities in patients initiating biologic therapy in BADBIR was 54%.
14 To identify an approximation for uncontrolled comorbidities (eTable 1 in the Supplement), patients with a diagnosis year matching or preceding the year of consent were designated ineligible. There was difficulty in mapping eligibility criteria from the trials to BADBIR. Criteria that were not applied to BADBIR included: washout periods (eligible participants would be washed out if commencing a clinical trial), pregnant or breastfeeding women (data not collected), and immunocompromised participants (adalimumab only). In total, 4 eligibility categories were identified: missing baseline PASI only (m-PASI), insufficient baseline PASI only (i-PASI), ineligible owing to satisfying at least 1 of the exclusion criteria in Table 1 , and eligible. The criteria applied to patients initiating etanercept, adalimumab, or ustekinumab are summarized in Table 1 .
Statistical Methods
Drug discontinuation was determined using the cumulative incidence of patients discontinuing therapy in the first 12 months by drug, eligibility category, and stop reason (adverse events, ineffectiveness, other, missing).
For effectiveness, baseline PASI values were identified if reported within 6 months of the drug start date (−183 to 0 days). The PASI values recorded between 4 to 8 months and 10 to 14 months after initiating therapy were used to determine response to treatment at 6 months and 12 months, respectively. Patients with a baseline, 6-month and 12-month PASI were included in the analysis. A 2-sample t test was used to determine differences between the ineligible and i-PASI categories with eligible patients for the median PASI values at all time points and absolute change at 6 and 12 months. Linear regression was used to identify predictors of absolute change in PASI at 6 and 12 months, with the eligible category as the reference group. The predictors included: ineligible and i-PASI categories, aged 70 years or older, body mass index (calculated as weight in kilograms divided by height in meters squared), 3 or more comorbidities, prevalent psoriatic arthritis, male sex, ever smoked (current or past). Selection bias between patients with complete PASI values and those with missing values at 6 and/or 12 months was investigated by determining whether the proportion of women, median age, and baseline PASI values differed (eTable 4 in the Supplement).
An incidence rate (IR) per 1000 person years was calculated by drug and eligibility category for SAEs reported in the first 12 months following treatment initiation; IRRs were calculated using Poisson regression between the eligibility categories with the eligible category as the reference group. All analyses were performed using Stata statistical software (version 13.1, StataCorp).
Results
Patient Characteristics
A total of 8533 patients were registered to the biologic cohort. Of those, 7408 (87%) completed at least 1 follow-up; 1509 (18%) patients registered to etanercept, 4000 (47%) registered to adalimumab, and 1627 (19%) registered to ustekinumab (eFigure1intheSupplement). The eligibility criteria extracted from phase 3 licensing trials were applied to patients registering to each biologic. Common criteria included: chronic plaque psoriasis; patients aged 18 years or older; a PASI value of 10 or higher (etanercept) or 12 or higher (adalimumab, ustekinumab); and exclusions for comorbidities, recent infections, and previous cancer ( Table 2 ). In total, 839 (56%) etanercept, 2219 (56%) adalimumab, and 754 (46%) ustekinumab patients were categorized as eligible (Table 1 (Table 2 ).
Drug Discontinuation
The cumulative incidence of drug discontinuation was similar between eligibility categories per drug ( Table 3) . The most common reason for discontinuation in the first 12 months of treatment was ineffectiveness for each eligibility category per drug (etanercept, 11%-15%; adalimumab, 6%-8%; ustekinumab, 3%-5%) with similar proportions stopping for adverse events (etanercept, 2%-4%; adalimumab, 3%-5%; ustekinumab, 2%-3%) (Table 3) .
Effectiveness
In the adjusted analysis, significantly smaller changes in PASI values were reported at 6 and 12 months for i-PASI patients for all 3 biologics, with significantly smaller changes in PASI values also reported for ineligible adalimumab patients (Table 4) . Increased BMI (adalimumab only) and 3 or more comorbidities (ustekinumab only) predicted a smaller absolute change in PASI at 6 or 12 months, whereas male sex predicted a significantly greater absolute change in PASI (etanercept at 6 months; adalimumab at 6 and 12 months) ( Table 4 ). 
Serious Adverse Events
Other Analyses
Clinical trials of biologics in psoriasis most commonly report PASI 75 (the proportion of patients achieving a 75% reduction in PASI values from baseline) as the primary outcome (eTable 1 in the Supplement). Differences in PASI 75 values at 6 months, 12 months, and both 6 and 12 months by eligibility category were determined using χ 2 test (eTable 2 in the Supplement).
Significantly lower proportions of ineligible patients achieved PASI 75 at 6 months, 12 months, or both 6 and 12 months compared with eligible patients. 
Abbreviation: i-PASI, insufficient baseline Psoriasis Area and Severity Index. The number of events and incidence rates per MedDRA SOC for each biologic and eligibility status are provided in eTable 4intheSupplement; the most common events were infections, neoplasms, and surgeries.
Discussion
Patients with psoriasis receiving biologic therapies who were identified as ineligible for clinical trials were twice as likely to experience an SAE and had significantly smaller absolute changes in PASI (adalimumab and ustekinumab) when compared with eligible patients in the first 12 months of treatment. However, eligibility status was not associated with the overall discontinuation rate because there were no differences between eligible and ineligible categories for any of the biologics investigated.
Key Findings
The eligibility criteria applied to clinical trials of biologics in patients with psoriasis creates a restricted sample in which the efficacy and safety of new therapies are investigated prior to licensing. In the present study, 367 (24%) etanercept, 282 (7%) adalimumab, and 394 (24%) ustekinumab patients were identified as ineligible for their respective biologic clinical trials. It is likely that patients categorized as m-PASI or i-PASI would be eligible for clinical trials because the drug discontinuation and SAE rates were comparable to those of patients categorized as eligible.
The cumulative incidence of discontinuing therapy in the first 12 months was similar for each stop reason and eligibility criteria per biologic (Table 3) . Patients who discontinued etanercept were more likely to do so for ineffectiveness, with fewer patients discontinuing adalimumab and ustekinumab in the first 12 months. The similarities in discontinuation rates by eligibility category per drug suggest survival analyses may not be good proxy measures for either effectiveness or safety outcomes.
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Eligible patients were significantly more likely to achieve a greater improvement in PASI values at 6 and 12 months compared with i-PASI patients for all 3 biologics and ineligible adalimumab patients (Table 4) (Table 2 ). There were also methodological reasons contributing to the efficacy-effectiveness gap in this study: baseline PASI in BADBIR can be reported up to 6 months prior to the biologic start date, therefore the baseline PASI may not capture true disease severity and will also influence the absolute change in PASI; and patients enrolled in the licensing trials extracted all received the highest permitted doses compared with 977 (65%) etanercept and 859 (53%) ustekinumab patients in BADBIR ( Table 2 ). The findings of the present study emphasize the difference between reports of efficacy and effectiveness 18 ;e xpectations of response levels should therefore be tempered in clinical practice. Patients categorized as ineligible were significantly more likely than eligible patients to experience an SAE in the first 12 months after initiating biologic therapy. Only 1 previous study has demonstrated the IRR of SAEs to be elevated by 2.6-fold (95% CI, 1.5-4.5) in 29.8% BIOBADADERM patients categorized as ineligible, 1 which is comparable to the IRR in the present study (Table 5) . However, a lower proportion of pa- ; ineligible patients in the present study had a greater number of comorbidities, similar to the previous study (Table 1) .
Limitations
Despite extracting criteria from articles of the licensing trials and additional sources where possible, only 282 (7%) patients were classified as ineligible for adalimumab resulting from fewer comorbidity exclusions extracted compared with etanercept and ustekinumab ( Table 1 ) (eTable 1 in the Supplement). This is likely to have introduced selection bias resulting in lower effectiveness and a higher SAE rate in the eligible adalimumab patients, and therefore an underestimation of the gap between the 2 populations in our results for adalimumab. However ; however, the rationale for the additional criteria is unclear. If any of the exclusion criteria are identified as unnecessary, newer biologic therapies could be tested in a more representative sample of patients with psoriasis to bridge the efficacy-effectiveness and safety gaps.
There were limitations in applying the extracted eligibility criteria to patients in BADBIR; comorbidities in BADBIR are reported with the year of onset and it was not possible to identify cases of "uncontrolled" comorbid conditions (eg, diabetes, psychiatric disorders) in the definitions reported. Exclusion of women of child-bearing potential who do not use contraceptives was also not possible to implement because only hormonal contraceptives are captured as a concomitant therapy with low levels of reporting (327 [6%] women). There was also a high proportion of missing data for 6-and/or 12-month PASI values (796 [58%] etanercept, 2230 [61%] adalimumab, 952 [63%] ustekinumab) (eTable 3 in the Supplement). Selection bias was explored between patients with missing and nonmissing PASI values for the effectiveness analysis with no significant differences in age or sex observed, but significant differences in baseline PASI values for ustekinumab only (eTable 3intheSupplement); therefore, patients included in the effectiveness analysis are considered to be representative of those with missing PASI values at either follow-up.
Conclusions
Patients identified as ineligible in BADBIR did not have the same levels of effectiveness and were at 2 to 3 times increased risk of developing SAEs in the first 12 months following initiation of biologic treatment compared with eligible patients, similar to previous findings. 1 Psoriasis patients enrolled in clinical trials of biologics are not representative of realworld patients, particularly those categorized as ineligible in the present study (higher BMI, more patients aged ≥70 years, and a greater number of comorbidities). Clinicians should be mindful of these differences when counselling patients on biologic treatment initiation based on evidence from clinical trials. All trials should publish their full protocol and justify the eligibility criteria selected; this would provide clinicians with a better understanding of the impact the trial results will likely have on their patients. from all three studies above and details additional eligibility criteria.
Figure S1 Flowchart of included patients
Specimen criteria (NCT00646191)
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---= not reported;  = reported as inclusion criterion; ID = identifier; IP = investigational product; PASI = Psoriasis Area and Severity Index; BSA = Body Surface Area; PGA = Physician's Global assessment; UV = ultraviolet; TNFi = tumour necrosis factor inhibitors; IL = interleukin; TB = tuberculosis; † www.amgentrials.com identifier; * "other than successfully treated NMSC or localized carcinoma in situ of the cervix"; ** except treated NMSC; ‡ doses reported are etanercept 50mg weekly, adalimumab 40mg fortnightly and ustekinumab 90mg 12 weekly after loading schedules were complete. © 2018 American Medical Association. All rights reserved. 0 ---i-PASI = insufficient baseline Psoriasis Area and Severity Index; n = number of events; IR = incidence rate; CI = confidence interval; MedDRA = Medical Dictionary for Regulatory Activities; SOC = System Organ Class; * no congenital events reported.
